Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX‐IOL study

Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome

(2021) Francesca Palandri et al.   CANCER

Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts

(2020) Haifa Kathrin Al‐Ali et al.   BRITISH JOURNAL OF HAEMATOLOGY

Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date

(2020) Sarah Bassiony et al.   Therapeutics and Clinical Risk Management

ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial

(2020) Stephen T. Oh et al.   Blood Advances

Primary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management

(2020) Ayalew Tefferi   AMERICAN JOURNAL OF HEMATOLOGY

Deferasirox in the management of iron‐overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda ( IRON ‐M study)

(2019) Elena M. Elli et al.   BRITISH JOURNAL OF HAEMATOLOGY

Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry

(2019) Marlijn Hoeks et al.   HAEMATOLOGICA

Iron toxicity – Its effect on the bone marrow

(2018) Alessandro Isidori et al.   BLOOD REVIEWS

Sustained Erythroid Response in a Patient with Myelofibrosis Receiving Concomitant Treatment with Ruxolitinib and Deferasirox

(2018) Eugenio Piro et al.   CHEMOTHERAPY

MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis

(2018) Paola Guglielmelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?

(2018) Ambra Di Veroli et al.   LEUKEMIA RESEARCH

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

(2017) Srdan Verstovsek et al.   Journal of Hematology & Oncology

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

(2017) Srdan Verstovsek et al.   Journal of Hematology & Oncology

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis

(2017) F Passamonti et al.   LEUKEMIA

Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis

(2017) Francesca Palandri et al.   Oncotarget

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes

(2016) Nicole Carreau et al.   BLOOD REVIEWS

Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase

(2015) Roberto Latagliata et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms

(2015) Mads Emil Bjørn et al.   MEDIATORS OF INFLAMMATION

Effects of Iron Overload on the Bone Marrow Microenvironment in Mice

(2015) Yuchen Zhang et al.   PLoS One

IRON CHELATION THERAPY WITH DEFERASIROX IN THE MANAGEMENT OF IRON OVERLOAD IN PRIMARY MYELOFIBROSIS

(2014) Elena Maria Elli et al.   Mediterranean Journal of Hematology and Infectious Diseases

Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis

(2013) Animesh Pardanani et al.   AMERICAN JOURNAL OF HEMATOLOGY

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

(2013) F. Cervantes et al.   BLOOD

Hematological improvement during iron-chelation therapy in myelodysplastic syndromes: The experience of the “Rete Ematologica Lombarda”

(2013) Alfredo Molteni et al.   LEUKEMIA RESEARCH

One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience

(2012) Ayalew Tefferi et al.   MAYO CLINIC PROCEEDINGS

Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS

(2010) C. Elena et al.   HAEMATOLOGICA

DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status

(2010) Naseema Gangat et al.   JOURNAL OF CLINICAL ONCOLOGY

Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis - prognostic relevance is independent of IPSS or karyotype

(2009) Ayalew Tefferi et al.   AMERICAN JOURNAL OF HEMATOLOGY

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

(2009) F. Passamonti et al.   BLOOD

Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy

(2009) Heather A. Leitch et al.   HEMATOLOGICAL ONCOLOGY

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

(2008) F. Cervantes et al.   BLOOD